TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of diffuse large B-cell lymphoma.

LEARNING OBJECTIVES

• Apply available research findings and consider various clinical and biologic factors in the formation of evidence-based therapeutic approaches for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
• Appreciate the scientific rationale for targeting CD79b in patients with DLBCL, and review published clinical research guiding the use of polatuzumab vedotin in disease treatment.
• Appraise emerging Phase III clinical trial data documenting the benefit of polatuzumab vedotin as a component of first-line therapy for patients with previously untreated DLBCL, and consider the implications of these findings for current clinical management algorithms.
• Compare and contrast the side effects associated with available and emerging first-line therapeutic strategies for patients with DLBCL, and formulate supportive care strategies to minimize and manage these toxicities.
• Recall ongoing clinical research evaluating novel treatment approaches for newly diagnosed DLBCL, and counsel appropriate patients regarding the potential benefits of trial participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
Audio Program: This CME activity consists of an audio component.
CME credit is no longer available for this issue

Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Christopher R Flowers, MD, MS
Chair, Professor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Spectrum Pharmaceuticals Inc; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Celgene Corporation, Cellectis, Eastern Cooperative Oncology Group, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, National Cancer Institute, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor, ZIOPHARM Oncology Inc; Data and Safety Monitoring Board/Committee: Denovo Biopharma.

Neha Mehta-Shah, MD, MSCI
Associate Professor of Medicine
Division of Oncology, Department of Medicine
Washington University School of Medicine
St Louis, Missouri

Consulting Agreements: C4 Therapeutics, Daiichi Sankyo Inc, Karyopharm Therapeutics, Kyowa Kirin Co Ltd, Ono Pharmaceutical Co Ltd, Secura Bio; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Innate Pharma, Secura Bio, Verastem Inc.

Grzegorz Nowakowski, MD
Professor of Oncology and Medicine
Vice Chair, Lymphoma Disease Group
Chair for Education
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Consulting Agreements: AbbVie Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Incyte Corporation, Kite, A Gilead Company, MorphoSys, Roche Laboratories Inc, Seagen Inc; Contracted Research: Incyte Corporation, MorphoSys, Roche Laboratories Inc, Seagen Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by an educational grant Genentech, a member of the Roche Group.

Release date: February 2022
Expiration date: February 2023